Komori
Pharma Foods International (2929) · FactTurnaround from quarterly profit to loss

Operating and ordinary profit turn positive in the third-quarter accounting period

First written in FY2018-Q3. 11 of 21 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2025-H1.

21entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2018-Q3 – FY2019-Q2AdvancedFY2021-Q2 – FY2022-Q1AdvancedFY2023-Q2 – FY20242018: 220182019: 320192020: 320202021: 320212022: 420222023: 320232024: 220242025: 1
Same theme, other companies
Transition from Profit to Loss in Quarterly PerformanceA theme 48 companies write about · 47 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 19 of 39 companies on the "Worse" side.

15 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 48 companies compared. The sentences above are computed from all 48.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1Turnaround from quarterly profit to lossAnnual report

    「Operating profit (¥ million) 933 1,730 1,847 882 △258 Ordinary profit (¥ million) 937 1,680 2,025 888 △243」

    In the standalone second quarter, the company posted an operating loss of ¥258 million and an ordinary loss of ¥243 million, turning from operating income of ¥882 million and ordinary income of ¥888 million in the first quarter to a loss.
  2. FY2024AdvancedAnnual report

    「Operating income for the consolidated fourth quarter was ¥1,847 million, while ordinary income was ¥2,025 million.」

    In the standalone fourth quarter as well, the company recorded operating income of ¥1,847 million and ordinary income of ¥2,025 million, maintaining quarterly profitability.
  3. FY2024-Q2AdvancedAnnual report

    「Operating results (¥ million) 1,310 2,518 1,976 601 933 Ordinary results (¥ million) 1,268 2,494 1,958 605 937」

    In the standalone second quarter, operating income was ¥933 million and ordinary income was ¥937 million, up from operating income of ¥601 million and ordinary income of ¥605 million in the previous quarter.
  4. FY2024-Q1AdvancedAnnual report

    「Operating results (¥ million) -2,194 1,310 2,518 1,976 601 Ordinary results (¥ million) -2,180 1,268 2,494 1,958 605」

    Operating income was ¥601 million and ordinary income was ¥605 million in the first quarter, turning from a quarterly loss in the same period of the previous year to a profit.
  5. FY2023AdvancedAnnual report

    「Operating results (¥ million) 1,976 Ordinary results (¥ million) 1,958」

    Standalone operating income of ¥1,976 million and ordinary income of ¥1,958 million were recorded for the fourth quarter, maintaining quarterly profitability.
  6. FY2023-Q2AdvancedAnnual report

    「Consolidated second-quarter period of the fiscal year under review: operating results (¥ million) 1,310 Ordinary results (¥ million) 1,268」

    On a standalone basis for the second quarter, operating income was ¥1,310 million and ordinary income was ¥1,268 million, recovering from a loss in the standalone first quarter to profitability.
  7. FY2023-Q1Return from quarterly profit to lossAnnual report

    「Operating results (¥ million) 1,575 457 -1,100 148 -2,194 Ordinary results (¥ million) 1,617 487 -1,028 188 -2,180」

    On a standalone basis for the first quarter, operating loss was ¥2,194 million and ordinary loss was ¥2,180 million, turning again from the profit in the fourth quarter of the previous fiscal year to a loss.
  8. FY2022AdvancedAnnual report

    「Operating results for the consolidated fourth-quarter period of the fiscal year under review were ¥148 million, and ordinary results were ¥188 million.」

    The fourth quarter recovered from the third-quarter loss to operating and ordinary income.
  9. FY2022-Q3Return from quarterly profit to lossAnnual report

    「Consolidated third-quarter period of the fiscal year under review Net sales (¥ million) 15,228 Operating results (¥ million) -1,100 Ordinary results (¥ million) -1,028」

    On a standalone basis for the third quarter, operating loss was ¥1,100 million and ordinary loss was ¥1,028 million, turning to a loss from operating income of ¥457 million and ordinary income of ¥487 million in the previous quarter.
  10. FY2022-Q2Continued quarterly profitability and lower earnings levelsAnnual report

    「Operating results (¥ million) 1,346 2,714 3,040 1,575 457 Ordinary results (¥ million) 1,356 2,765 3,050 1,617 487」

    On a standalone basis for the second quarter of the fiscal year under review, operating income of ¥457 million and ordinary income of ¥487 million were recorded, maintaining quarterly profitability. However, the earnings level declined from operating income of ¥1,575 million in the first quarter.
  11. FY2022-Q1AdvancedAnnual report

    「Operating results (¥ million) -1,428 1,346 2,714 3,040 1,575 Ordinary results (¥ million) -1,405 1,356 2,765 3,050 1,617」

    Standalone operating income for the first quarter of the fiscal year under review was ¥1,575 million and ordinary income was ¥1,617 million, turning from losses in the first quarter of the previous year to profits.
  12. FY2021-Q3AdvancedAnnual report

    「As a result, operating income for the third quarter of the fiscal year under review reached a record ¥2,714 million for a quarter.」

    Standalone operating income for the third quarter was ¥2,714 million, setting a new quarterly record.
  13. FY2021-Q2AdvancedAnnual report

    「As a result, operating income for the second quarter of the fiscal year under review reached a record ¥1,346 million for a quarter.」

    Standalone operating income for the second quarter reached a record ¥1,346 million, indicating progress in recovering earnings from the quarterly losses through the previous quarter.
  14. FY2021-Q1Return from quarterly profit to lossAnnual report

    「The quarterly performance trend from the consolidated first quarter of the previous fiscal year through the consolidated first quarter of the fiscal year under review is as follows.」

    From operating income of ¥997 million and ordinary income of ¥1,014 million in the third and fourth quarters of the previous fiscal year, the first quarter of the fiscal year under review again fell into a quarterly loss, with an operating loss of ¥1,428 million and an ordinary loss of ¥1,405 million.
  15. FY2020-Q3AdvancedAnnual report

    「Operating income for the third quarter of the fiscal year under review reached a record ¥1,328 million, reflecting the successful generation of earnings through proactive investment.」

    Standalone operating income for the third quarter was ¥1,328 million and ordinary income was ¥1,353 million, progressing from losses through the previous quarter to a record quarterly profit.
  16. FY2020-Q2RestatedAnnual report

    「Operating results (¥ million) 103 167 696 -784 -800 Ordinary results (¥ million) 113 181 705 -767 -810」

    On a standalone basis for the second quarter, operating results were a loss of ¥800 million and ordinary results were a loss of ¥810 million, indicating a quarterly loss following the first quarter.
  17. FY2020-Q1Return from quarterly profit to lossAnnual report

    「Operating results (¥ million) -391 103 167 696 -784 Ordinary results (¥ million) -362 113 181 705 -767」

    After quarterly profits continued from the second through fourth quarters of the previous fiscal year, the first quarter of the fiscal year under review again fell into loss, with an operating loss of ¥784 million and an ordinary loss of ¥767 million.
  18. FY2019-Q3AdvancedAnnual report

    「Operating results (¥ million) 623 535 -391 103 167 Ordinary results (¥ million) 637 554 -362 113 181」

    On a standalone basis for the third quarter, operating income was ¥167 million and ordinary income was ¥181 million, recording a quarterly profit following operating income of ¥103 million and ordinary income of ¥113 million in the second quarter.
  19. FY2019-Q2Return to quarterly profitabilityAnnual report

    「Operating results (¥ million) -379 623 535 -391 103 Ordinary results (¥ million) -377 637 554 -362 113」

    On a standalone basis for the second quarter, operating income was ¥103 million and ordinary income was ¥113 million, turning from a loss in the first quarter to quarterly profitability.
  20. FY2019-Q1Turnaround from quarterly profit to lossAnnual report

    「Operating results (¥ million) -483 -379 623 535 -391 Ordinary results (¥ million) -455 -377 637 554 -362」

    From the operating and ordinary income reported as profitable for the third and fourth quarters shown previously, the first quarter of the fiscal year under review returned to quarterly losses, with an operating loss of ¥391 million and an ordinary loss of ¥362 million.
  21. FY2018-Q3First statedAnnual report

    「Operating results (¥ million) 623 Ordinary results (¥ million) 637」

    The quarterly performance trend disclosed that, on a standalone basis for the third quarter, operating results were profitable at ¥623 million and ordinary results were profitable at ¥637 million.
Moved together

" 적극ive efforts under the Foods with Function Claims system" moved the same way as this thread, in the same document, in 11 of its 21 moves.

1199888★123456
  1. ★This thread
  2. 1 적극ive efforts under the Foods with Function Claims system11×
  3. 2Research and Development Expenditure9×
  4. 3Policy of proactively considering dividends while prioritizing retained earnings9×
  5. 4Development of antibody therapeutics using proprietary chicken antibody technology8×
  6. 5Functional Materials business: lower revenue and profit8×
  7. 6Decline in Cash and Cash Equivalents8×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Operating and ordinary profit turn positive in the third-quarter accounting period | Pharma Foods International Co.,Ltd. (2929) | Komori